Results 31 to 40 of about 106,112 (301)
International Journal of Infectious Diseases, 2021 Objectives: The purpose of this study is to evaluate clinical outcomes in patients with critical COVID-19 pneumonia requiring invasive mechanical ventilation who were treated with tocilizumab Design: Single-center retrospective cohort study Setting ...
Matthew J. Fisher +4 more
doaj +1 more source
Theoretical impact of insecticide-impregnated school uniforms on dengue incidence in Thai children. [PDF]
, 2013 BACKGROUND: Children carry the main burden of morbidity and mortality caused by dengue. Children spend a considerable amount of their day at school; hence strategies that reduce human-mosquito contact to protect against the day-biting habits of Aedes ...
Amaku, Marcos +4 more
core +2 more sources
Case Reports in Immunology, 2016 Tocilizumab is an interleukin-6 receptor inhibitor licensed for moderate to severe rheumatoid arthritis (RA). We report a case of Tocilizumab monotherapy for severe active RA in a patient with coexisting ulcerative colitis (UC).
Matthew Chak Hin Szeto +3 more
doaj +1 more source
An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy [PDF]
, 2015 Objective: To evaluate associations between lipid levels, inflammation, and rheumatoid arthritis (RA) disease activity, at baseline and during treatment, with the risk of major adverse cardiovascular events (MACE) in tocilizumab‐treated patients with RA.
Bathon, Joan M. +7 more
core +1 more source
Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration [PDF]
, 2020 Background Immune checkpoint inhibitors such as nivolumab and targeted BRAF inhibitors have dramatically altered the treatment outcomes of metastatic melanoma over the past few years. Skin toxicity is the most common adverse event (AE) related to the
Maestro, Alessandra +3 more
core +1 more source
Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells.
PLoS ONE, 2020 Tocilizumab is a humanized monoclonal antibody that is approved for the treatment of different human inflammatory diseases, including rheumatoid arthritis and cytokine release syndrome.
Juliane Lokau +7 more
doaj +1 more source
Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction
Open Heart, 2021 Objective Beyond reducing inflammation and troponin T (TnT) release, the interleukin-6 receptor antagonist tocilizumab reduces neutrophil counts in patients with non-ST segment elevation myocardial infarction (NSTEMI). It is unclear if this is related to
Thor Ueland +10 more
doaj +1 more source
Treatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic in a global comparative observational study [PDF]
, 2017 Objective To compare clinical effectiveness between tocilizumab and tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) and inadequate response to conventional synthetic disease-modifying antirheumatic drugs initiating ...
Aassi, Maher +4 more
core +3 more sources
Scientific Reports, 2022 We compared the efficacy of tocilizumab and etanercept in inhibiting radiographic progression of joint destruction in rheumatoid arthritis. Overall, 187 patients treated with etanercept or tocilizumab were selected.
Shinya Hayashi +11 more
doaj +1 more source
International Journal of Infectious Diseases, 2023 Objectives: Interleukin (IL)-6 inhibitors are administered to treat patients hospitalized with COVID-19. In 2021, due to shortages, different dosing regimens of tocilizumab, and a switch to sarilumab, were consecutively implemented. Using real-world data,
Maaike C. Swets +12 more
doaj +1 more source